Expression of Estrogen Receptor Alpha in Malignant Melanoma

Document Type : Original Article


Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran


Background: Features of malignant melanoma (MM) vary in the different geographic regions of the world. This may be attributable to environmental, ethnic, and genetic factors. The aim of this study was to determine the expression of estrogen receptor alpha (ER-α) in MM in Isfahan, Iran. Materials and Methods: This study was planned as a descriptive, analytical, cross-sectional investigation. During this study, paraffin-embedded tissue blocks of patients with a histopathologic diagnosis of MM was studied for ER-α using immunohistochemistry (IHC). Results: In this study, 38 patients (female/male; 20/18) with a definite diagnosis of malignant cutaneous melanoma and mean age of 52.4 ± 11.2 years were investigated. Using envision IHC staining, there were not any cases with ER-α expression. Conclusion: In confirmation to the most previous studies, expression of ER-α was negative in MM. It is recommended to investigate the expression of estrogen receptor beta and other markers in MM.


Mackie RM, Quinn AG. Non melanoma skin cancer and other epidermal skin tumors. In: Burns T, Breathnach S, Cox N, editors. Textbook of Dermatology. 7th ed., Vol. 3. USA: Blackwell Scientific Publications; 2004. p. 1-50.  Back to cited text no. 1
Krueger H, Williams D, Chomiak M, Trenaman L. The Economic Burden of Skin Cancer in Canada: Current and Projected. Toronto, ON: Canadian Partnership Against Cancer; 2010. Available from: [Last cited on 2012 Jul 24].  Back to cited text no. 2
Shoo BA, Kashani-Sabet M. Melanoma arising in African-, Asian-, Latino- and Native-American populations. Semin Cutan Med Surg 2009;28:96-102.  Back to cited text no. 3
Noorbala MT, Kafaie P. Analysis of 15 years of skin cancer in central Iran (Yazd). Dermatol Online J 2007;13:1.  Back to cited text no. 4
Erdei E, Torres SM. A new understanding in the epidemiology of melanoma. Expert Rev Anticancer Ther 2010;10:1811-23.  Back to cited text no. 5
de Braud F, Khayat D, Kroon BB, Valdagni R, Bruzzi P, Cascinelli N. Malignant melanoma. Crit Rev Oncol Hematol 2003;47:35-63.  Back to cited text no. 6
Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001;93:824-42.  Back to cited text no. 7
Armstrong BK. Cutaneous malignant melanoma. In: Schottenfeld DF, Joseph F Jr, editors. Cancer Epidemiology and Prevention. New York: Oxford University Press; 1996. p. 1223.   Back to cited text no. 8
Strouse JJ, Fears TR, Tucker MA, Wayne AS. Pediatric melanoma: Risk factor and survival analysis of the surveillance, epidemiology and end results database. J Clin Oncol 2005;23:4735-41.  Back to cited text no. 9
Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 2005;19:1951-9.  Back to cited text no. 10
Mann M, Cortez V, Vadlamudi RK. Epigenetics of estrogen receptor signaling: Role in hormonal cancer progression and therapy. Cancers (Basel) 2011;3:1691-707.  Back to cited text no. 11
Yakimchuk K, Jondal M, Okret S. Estrogen receptor α and ß in the normal immune system and in lymphoid malignancies. Mol Cell Endocrinol 2013;375:121-9.  Back to cited text no. 12
Mauro LV, Bellido M, Morandi A, Bonadeo F, Vaccaro C, Quintana GO, et al. Association between mast cells of different phenotypes and angiogenesis in colorectal cancer. Mol Med Rep 2008;1:895-902.  Back to cited text no. 13
Ibaraki T, Muramatsu M, Takai S, Jin D, Maruyama H, Orino T, et al. The relationship of tryptase- and chymase-positive mast cells to angiogenesis in stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2005;28:617-21.  Back to cited text no. 14
Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am 2011;20:1-17.  Back to cited text no. 15
Li Y, Meeran SM, Patel SN, Chen H, Hardy TM, Tollefsbol TO. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer. Mol Cancer 2013;12:9.  Back to cited text no. 16
Fagan DH, Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2008;13:423-9.  Back to cited text no. 17
Driggers PH, Segars JH. Estrogen action and cytoplasmic signaling pathways. Part II: The role of growth factors and phosphorylation in estrogen signaling. Trends Endocrinol Metab 2002;13:422-7.  Back to cited text no. 18
Gould Rothberg BE, Rimm DL. Biomarkers: The useful and the not so useful – An assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol 2010;130:1971-87.  Back to cited text no. 19
Mori T, Martinez SR, O'Day SJ, Morton DL, Umetani N, Kitago M, et al. Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res 2006;66:6692-8.  Back to cited text no. 20
Greenberg ES, Chong KK, Huynh KT, Tanaka R, Hoon DS. Epigenetic biomarkers in skin cancer. Cancer Lett 2014;342:170-7.  Back to cited text no. 21
Volkovova K, Bilanicova D, Bartonova A, Letašiová S, Dusinska M. Associations between environmental factors and incidence of cutaneous melanoma. Review. Environ Health 2012;11 Suppl 1:S12.  Back to cited text no. 22
Lecavalier MA, From L, Gaid N. Absence of estrogen receptors in dysplastic nevi and malignant melanoma. J Am Acad Dermatol 1990;23 (2 Pt 1):242-6.  Back to cited text no. 23
Duncan LM, Travers RL, Koerner FC, Mihm MC Jr, Sober AJ. Estrogen and progesterone receptor analysis in pregnancy-associated melanoma: Absence of immunohistochemically detectable hormone receptors. Hum Pathol 1994;25:36-41.  Back to cited text no. 24
Schmidt AN, Nanney LB, Boyd AS, King LE Jr, Ellis DL. Oestrogen receptor-beta expression in melanocytic lesions. Exp Dermatol 2006;15:971-80.  Back to cited text no. 25
Ohata C, Tadokoro T, Itami S. Expression of estrogen receptor beta in normal skin, melanocytic nevi and malignant melanomas. J Dermatol 2008;35:215-21.  Back to cited text no. 26
de Giorgi V, Mavilia C, Massi D, Gozzini A, Aragona P, Tanini A, et al. Estrogen receptor expression in cutaneous melanoma: A real-time reverse transcriptase-polymerase chain reaction and immunohistochemical study. Arch Dermatol 2009;145:30-6.  Back to cited text no. 27
Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 2001;61:7025-9.  Back to cited text no. 28
Tang B, Jiang J. Study of the CpG methylation status of ER alpha gene in estrogen receptor alpha-negative breast cancer cell lines and the role of hydralazine demethylation. Zhonghua Bing Li Xue Za Zhi 2005;34:283-7.  Back to cited text no. 29
Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986;321:209-13.  Back to cited text no. 30
Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H. Melanoma: New insights and new therapies. J Invest Dermatol 2012;132 (3 Pt 2):854-63.  Back to cited text no. 31